Skip to main navigation
RayzeBio
  • Approach
  • Pipeline
  • Team
  • Investors
    • Corporate Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • IR Resources
      • Email Alerts
      • Contact IR
  • Contact
  • Corporate Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Annual Reports
  • IR Resources
    • Email Alerts
    • Contact IR
hero background

News Releases

September 19, 2023
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
View News
September 14, 2023
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
View News
August 29, 2023
RayzeBio Appoints Christy Oliger to its Board of Directors
View News
June 21, 2023
RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
View News
May 31, 2023
RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
View News
May 22, 2023
RayzeBio to Present at Upcoming Medical Conferences
View News
March 21, 2023
RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer
View News
March 20, 2023
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
View News
January 4, 2023
RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023
View News

©2022 RayzeBio | Terms of Use | Privacy Policy | LinkedIn

MENU
  • Approach
    • Overview
    • Discovery Capabilities
    • Manufacturing
  • Pipeline
    • Overview
    • GEP-NETs
    • ES-SCLC
    • Hepatocellular Carcinoma
    • Posters & Presentations
  • Team
    • Team
    • Careers
  • Investors
    • Corporate Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • IR Resources
      • Email Alerts
      • Contact IR
  • Contact